Haematological Cancer Clinical Advisory Group

Investigational and Clinical Guidelines

June 2023

Revision due: April 2025

SWAG Haematology CAG

VERSION CONTROL

THIS IS A CONTROLLED DOCUMENT. PLEASE DESTROY ALL PREVIOUS VERSIONS ON RECEIPT OF A NEW VERSION.

Please check the SWAG website for the latest version available <u>here</u>.

VERSION	DATE ISSUED	SUMMARY OF CHANGE	OWNER'S NAME
0.1	May 2015	First draft	SWAG Haematology SSG
1.0	30 th June 2015	Finalised	
1.0			S Otton
1.1	30 th August 2016	Revision of lymphoma , and leukaemia pathways	H Dunderdale
1.2	31 st October 2016	Addition of link to NICE myeloma guidance	H Dunderdale
1.3	April 2017	Biennial review	SWAG Haematology MDT Leads
1.4	22 nd June 2017	Revision of clinical	D Mannari, H
		guidelines: addition of	Dunderdale
		links to national	
		guidelines and protocols	
1.5	30 th June 2017	Finalised	H Dunderdale
1.6	30 th May 2019	Biennial review and	H Dunderdale
		rebranding from Site	
		Specific Group to Clinical	
		Advisory Group	
1.7	June 2022	Biennial review (delayed	H Dunderdale
		due to the COVID-19	
		pandemic)	
1.8	June 2023	Removal of signature	H Dunderdale
		table in line with removal	
		of sign off by the SWAG	
		Cancer Alliance Lead	

This document was edited by:

Richard Lush, Chair of the SWAG Haematological Cancer CAG, Consultant Haematologist, Gloucestershire Hospitals NHS Foundation Trust

Deepak Mannari, previous Chair of the SWAG Haematology CAG, Consultant Haematologist, Taunton and Somerset NHS Foundation Trust & Yeovil District Hospitals NHS Foundation Trust

Sophie Otton, previous Chair of the SWAG Haematology CAG, Consultant Haematologist, North Bristol NHS Foundation Trust

Helen Dunderdale, SWAG Cancer Network CAG Support Manager



Haematology CAG Contents

Section	Contents	Measures	Page
1	Introduction		4
2	Investigational Guidelines	NS/Haem/g-17-102	5
3	Clinical Guidelines	NS/Haem/g-17-101	6
4	Pathways		9
4.1	Best Practice Acute Leukaemia Cancer Care Pathway		9
4.2	Hodgkin Lymphoma Cancer Care Pathway		10
4.3	Follicular lymphoma and other indolent lymphomas & diffuse large B-cell lymphoma cancer care pathway		11

1. Introduction

The following guidelines pertain to the local management of haematology malignancies for the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Network Haematological Cancer Clinical Advisory Group (CAG).

The CAG refers to the <u>British Society for Haematology</u> (BSH), <u>Guideline Central</u>(GC), the <u>European</u> <u>Society for Medical Oncology</u> (ESMO), and <u>National Institute for Health and Clinical Excellence</u> <u>Guidelines</u> (NICE).

Primary care clinicians should refer to the NICE guidelines *Suspected Cancer: recognition and management of suspected cancer in children, young people and adults* (2015) for information on the signs and symptoms that are relevant when considering referrals to the Haematology Oncology Services.

The guidelines should be reviewed alongside three other key documents for the CAG: the Constitution, Annual Report and the Work Programme. The Haematology CAG Constitution provides an overview of how the CAG operates, outlining the general working processes, patient referral pathways and the guidelines to which the CAG adheres. The Annual Report reflects the period of activity for the CAG from the previous year. It contains a summary of the activity of the Haematology CAG for this period measured against several key performance indicators that have been outlined in the National Quality Surveillance Programme. The Work Programme summarises the key areas for growth, development and improvement of the CAG over the next financial year (and beyond where



appropriate). All four documents should be reviewed together to give a full overview of the CAG, its performance, and future plans.

The CAG is committed to offering all eligible patients entry into clinical trials where available. A list of open trials is available on the SWAG website here.

2. Haematology CAG agreed Investigational Guidelines (NS/Haem/g-17-102)

The Haematology CAG aspires to host a centralised Specialist Integrated Haematology Malignancy Diagnostic Service (SIHMDS) in Severn Laboratory North Bristol Trust, and work is underway to define how laboratories work based on a network model. This preserves local reporting at treatment centres and centralises specialist testing, all of which are planned to be reported on to the HiLIS software system (awaiting implementation in UHBW).

Diagnostic services are available in North Bristol Trust, Gloucestershire Hospitals, Royal United Hospital Bath, Somerset Trust and University Hospitals Bristol and Weston. The CAG agrees to follow the guidelines as recommended by the <u>Royal College of Pathologists</u> (RCP) and the <u>British Society</u> <u>for Haematology</u>(BSH). Local laboratory investigational algorithms that meet the following required criteria are in place:

- Categorisation of suspected disease and relevant clinical / haematological presenting problems
- Multiple investigational modalities are used to confirm a given patient's diagnosis, so that the results of one modality may be used to corroborate those of another
- Allowable options for choices between investigations, specifying how the investigational pathway may be redirected at any point in the process, depending on results up to that point. Choices of investigation and decisions to redirect the pathway will be allowable at the behest of the investigating laboratory alone, as well as that of the referring clinician

North Bristol Trust refers to the investigational guidelines in Table 1. These can be found on the SWAG website here.

Investigational Guidelines	Trusts
BHODS Diagnostic Pathways for	North Bristol Trust
Haematological Malignancies (2013), Version	
3.0	
LP-SI-HMDS_BM Processing Overview	University Hospitals Bristol NHS Foundation
(2014), Edition 1	Trust
	Weston Area Health Trust
MF-SI-HMDS-VALVERWorkflow (2009),	University Hospitals Bristol NHS Foundation
Edition 1	Trust

Table 1:

Royal United Hospitals Bath NHS Foundation Trust, Taunton and Somerset NHS Foundation Trust, Yeovil NHS Trust and Gloucestershire Hospitals NHS Foundation Trust broadly agree with the above guidelines, but follow local standard operating procedures.

The Laboratories in the Trusts within the network group handle and transport samples in accordance with the Human Tissue Act (2014). Laboratories have CPA accreditation.

The individual Trusts have local agreements with the clinical commissioning groups (CCGS) that relate to the time limits by which reports are to be produced.

3. Haematology CAG Clinical Guidelines (NS/Haem/g-17-101)

The sub-speciality of Haematology is in the very happy position of having a whole range of respected National and International Clinical Guidelines available and used by the international community. The guidelines are frequently updated in view of the rapid advancement in diagnosis and management. In addition, for certain conditions in the UK, National MRC badged trials offer standardised protocols to follow even if patients are not considered for trial, available <u>here</u>. The Network and individual trusts are expected to follow these guidelines.

Generic Guidelines	Source	Publication date
Haematological cancers: improving outcomes	NICE	May 2016
Acute leukaemia and other myeloid disorders	Source	Publication date
Acute Lymphoblastic Leukaemia Clinical Practice Guidelines UKALL14 & UKALL60+ trials	ESMO	2016
Acute Lymphoblastic Lymphoma: Clinical Practice Guidelines	ESMO	2016
Diagnosis and management of acute myeloid leukaemia in adults AML18 & AML19 & LI-1 trial	BSH	2010
Management of AML in Pregnancy	BSH	2015
Hairy Cell Leukaemia: Clinical Practice Guidelines Diagnosis and Therapy of Hairy Cell Leukaemia	ESMO BSH	2015 2011

SWAG Haematology CAG

Investigational and Clinical Guidelines




Diagnosis and Management of Adult Myelodysplastic Syndromes	BSH	2013
Iron Chelation Therapy in Myelodysplastic Syndromes (Also refer to the BSH MDS Guidelines)	Advances in Haematolog Y	2010
Upfront Epo-GCSF (EpoG) Combined Therapy in Sideroblastic subtypes of MDS	Blood	2013
Chronic Myeloid Leukaemia: Clinical Practice Guidelines	ESMO	2012
Investigation and Management of Chronic Lymphocytic Leukaemia	BSH	2012
Lymphoid diseases	Source	Publication date
First Line Management of Classical Hodgkin Lymphoma	BSH	2014
Non-Hodgkin's Lymphoma: diagnosis and management	NICE	2016
Management of Primary Resistant and Relapsed Classical Hodgkin Lymphoma	BSH	2013
Investigation and Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma (LPNHL)	BSH	2015
Investigation and Management of Follicular Lymphoma	BSH	2011
Diffuse Large B-cell Lymphoma (DLBCL)	BSH	2016
<u>Consensus Guidelines – Diffuse Large B-cell Lymphoma,</u> Follicular Lymphoma, Chronic Lymphocytic Lymphoma	ESMO	2013
BSH Guidelines have yet to be published and management of Primary Central Nerve System Lymphoma (PCNSL) is currently controversial. The current standard is for fit patients to be		



treated with the <u>MATRIX</u> regime, available on the SWCN website here.		
Primary Central Nervous System Lymphoma (PCNSL)	Belgian Journal of Haematolog Y	2016
Investigation and Management of Mantle Cell Lymphoma	BSH	2012
Waldenstrom's Macroglobulinaemia	BSH	2014
Gastric Marginal Zone Lymphoma of MALT type: Clinical Practice Guidelines	ESMO	2013
		D 111
Plasma cell malignancies	Source	Publication date
Plasma cell malignancies Multiple Myeloma: Clinical Practice Guidelines	Source	
Multiple Myeloma: Clinical Practice Guidelines	Source ESMO	
Multiple Myeloma: Clinical Practice Guidelines http://www.b-s-h.org.uk/guidelines/guidelines/supportive-	ESMO	
Multiple Myeloma: Clinical Practice Guidelines http://www.b-s-h.org.uk/guidelines/guidelines/supportive-care-in-multiple-myeloma/ http://www.b-s-h.org.uk/guidelines/guidelines/screening-and-management-of-late-and-long-term-consequences-of-	ESMO BSH	
Multiple Myeloma: Clinical Practice Guidelines http://www.b-s-h.org.uk/guidelines/guidelines/supportive-care-in-multiple-myeloma/ http://www.b-s-h.org.uk/guidelines/guidelines/screening-and-management-of-late-and-long-term-consequences-of-myeloma-and-its-treatment/ http://www.b-s-h.org.uk/guidelines/guidelines/diagnosis-	ESMO BSH BSH	date
Multiple Myeloma: Clinical Practice Guidelines http://www.b-s-h.org.uk/guidelines/guidelines/supportive-care-in-multiple-myeloma/ http://www.b-s-h.org.uk/guidelines/guidelines/screening-and-management-of-late-and-long-term-consequences-of-myeloma-and-its-treatment/ http://www.b-s-h.org.uk/guidelines/guidelines/diagnosis-and-investigation-of-al-amyloidosis/ http://www.b-s-h.org.uk/guidelines/guidelines/management-of-and-investigation-of-al-amyloidosis/	ESMO BSH BSH BSH	date

4. Pathways






4.1 Best Practice Acute Leukaemia Cancer Care Pathway

4.2 Best Practice Hodgkin Lymphoma Cancer Care Pathway

SWAG Haematology CAG


Investigational and Clinical Guidelines





SWAG Haematology CAG

4.3 Best Practice Follicular lymphoma and other indolent lymphomas & diffuse large B-cell lymphoma cancer care pathway



END